Every 10-Q that Fortrea Holdings Inc. (FTRE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FTRE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FTRE filings page.
Fortrea Holdings (FTRE) filed its Q3 2025 10‑Q. Revenue rose to $701.3 million from $674.9 million a year ago, and the operating loss narrowed to $8.6 million. For the first nine months, revenue reached $2,062.9 million and net loss was $953.7 million, largely reflecting $797.9 million of goodwill impairments recorded in the first half.
Cash from operations for the nine months was $(15.6) million versus $245.7 million last year; cash ended at $131.3 million. The company sold $300.0 million of receivables under its securitization program and reported unearned revenue of $411.6 million, indicating contracted work in progress. Long‑term debt stood at $1,052.1 million, and Fortrea intends to repurchase up to $75.7 million of its 7.50% senior notes due 2030 pursuant to the asset sale covenant. Q3 segment operating income was $21.1 million.
Fortrea reports one segment (Clinical Services) and noted customer concentration, with one customer accounting for 19.8% of Q3 revenue. On June 11, 2025, the Board adopted a limited-duration stockholder rights plan.